|
 |
Tizanidine HydrochlorideThis page contains recent news articles, when available, and an overview of Tizanidine Hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Earthtimes (press release) Acorda Therapeutics Reports Third Quarter 2009 Financial Results - Nov 3, 2009 Financial Results and Product Update Zanaflex Capsules® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) Tablets gross sales - For the ... Reuters Acorda Therapeutics to Host Conference Call to Report Third Quarter 2009 ... - Oct 27, 2009 The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Reuters Acorda Therapeutics Announces Completion of Zanaflex Capsules(TM) … - Jan 8, 2007 The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride). "I'm pleased that we were able to complete the expansion of the sales force so ... $4.95 - Business Wire - ECNext Acorda Therapeutics Reports Second Quarter 2006 Financial Results. - Aug 3, 2006 For the quarter ended June 30, 2006, gross sales were $3.9 million for Zanaflex Capsules(TM) (tizanidine hydrochloride) and $4.0 million for Zanaflex(R) ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) … - Oct 17, 2006 The Acorda sales team promotes Zanaflex Capsules(TM) (tizanidine hydrochloride). "This second expansion will allow us to reach a much greater number of ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Reports Third Quarter 2008 Financial Results - Nov 4, 2008 Zanaflex Capsules ® (tizanidine hydrochloride) and Zanaflex ® (tizanidine hydrochloride) Tablets Gross Sales - For the quarter ended September 30, 2008, ... International Business Times Acorda Therapeutics Files Lawsuit Against Apotex Corp. and Apotex... - Oct 11, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 … - Feb 11, 2008 For the fourth quarter ended December 31, 2007, the Company reported gross sales of Zanaflex Capsules (tizanidine hydrochloride) of $11.8 million and gross ... Lifescience-online Acorda Therapeutics Reports Third Quarter 2006 Financial Results. - Nov 2, 2006 For the quarter ended September 30, 2006, gross sales of Zanaflex Capsules[TM] (tizanidine hydrochloride) were $5.0 million and gross sales of Zanaflex([R]) ... Free with registration - Business Wire - AccessMyLibrary.com NovaDel Announces Positive Data from Pilot Pharmacokinetic Study … - Apr 7, 2008 This Pilot Pharmacokinetic Study was designed to compare the PK profile of 2 mg, 4 mg and 8 mg Oral Spray (OS) doses of tizanidine hydrochloride to a 4 mg ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Files Lawsuit Against Apotex Corp. And Apotex... - Oct 15, 2007 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Medical News Today - Medical News Today (press release) Acorda Therapeutics Launches ZANAFLEX CAPSULES for the … - Apr 4, 2005 HAWTHORNE, NY -- Acorda Therapeutics(R) announced today that it has launched ZANAFLEX(R) CAPSULES (tizanidine hydrochloride), a new, capsule formulation of ... $4.95 - Business Wire - ECNext Paul Royalty Fund Purchases Revenue Interest in Acorda's Zanaflex … - Jan 19, 2006 Both products contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity. ... Free with registration - PR Newswire - AccessMyLibrary.com Acorda Therapeutics Names John Librie Senior Vice President, Sales … - Apr 3, 2008 Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules(R) (tizanidine hydrochloride), as well as oversee all pre-commercial ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Reports First Quarter 2008 Financial Results - May 5, 2008 Zanaflex(R) (tizanidine hydrochloride) Gross Sales - For the quarter ended March 31, 2008, the Company reported gross sales of Zanaflex Capsules(R) ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics.(Update) | Article from Medical Marketing & Media... - Feb 1, 2007 The sales team promotes Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles. - Nov 3, 2006 Acorda's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex[R] (tizanidine hydrochloride) tablets. ... $4.95 - Business Wire - ECNext Loislaw Federal District Court Opinions - ACORDA THERAPEUTICS, INC. … - Dec 29, 2008 02-1447 for tizanidine hydrochloride capsules, which the FDA approved on August 29, 2002. (Id., ¶ 10.) Apotex Inc. filed an Abbreviated New Drug Application ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Press Release: Paul Royalty Fund Purchases Revenue Interest in … - Jan 19, 2006 Both products contain tizanidine hydrochloride, or tizanidine, one of the two leading treatments currently used for the management of spasticity. ... Pay-Per-View - PR Newswire - HighBeam Research Acorda Therapeutics to Host Conference Call to Report Second - Aug 5, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Bloomberg Acorda Therapeutics to Present at the Piper Jaffray 20th Annual - Nov 25, 2008 The Company's marketed products include Zanaflex Capsules^® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Bloomberg Acorda Therapeutics' President and CEO Ron Cohen, MD Named Ernst … - Jun 29, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Strengthens Patent Portfolio on the Neuregulins. - Jul 11, 2005 The Company's marketed products include ZANAFLEX(R)CAPSULES (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics Presents Positive Data from Preclinical - Jul 30, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Bloomberg Acorda Therapeutics Announces Two Additions To Senior Management … - Aug 1, 2005 The Company's marketed products include ZANAFLEX(R)CAPSULES (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at RBC Capital Markets - Dec 4, 2008 The Company's marketed products include Zanaflex Capsules^® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Bloomberg Acorda Therapeutics to Present at the Acumen BioFin Rodman & … - Oct 31, 2007 The Company's marketed products include Zanaflex Capsules[TM] (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Announces Addition to Board of Directors. - Apr 7, 2005 The Company's marketed products include ZANAFLEX(R)CAPSULES (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at the 2007 UBS Global Life Sciences … - Sep 19, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Provides Update on Clinical Development of … - Dec 8, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics(R) Initiates Phase 3 Clinical Trial of Fampridine... - Jun 30, 2005 The Company's marketed products include Zanaflex(R) Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at Bank of America Health Care … - May 23, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Acorda Therapeutics to Receive Up to $10 Million from ... - Nov 28, 2006 The Company's marketed products include Zanaflex Capsules™ (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... FierceBiotech Acorda Therapeutics Responds to Third Point Letter - Feb 23, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Added to NASDAQ Biotechnology Index. - Nov 16, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - M2 Presswire - ECNext Acorda Therapeutics to Host Conference Call to Report First Quarter... - May 10, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... businesswire.com Acorda Therapeutics to Host Conference Call to Report Fourth Quarter ... - Mar 31, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... businesswire.com Acorda Therapeutics Reports First Quarter 2007 Financial Results - May 2, 2007 8, 2007, the Company announced it had completed the expansion of its sales force for Zanaflex Capsules(TM) (tizanidine hydrochloride) to 65 people, ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Reports First Quarter 2006 Financial Results - May 5, 2006 For the quarter ended March 31, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $2.3 million and gross sales of Zanaflex(R) ... Genetic Engineering News - Genetic Engineering News (press release) Emerging Markets Consulting, LLC. : Emerging Equity Alerts. - Jan 30, 2008 The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - M2 Presswire - AccessMyLibrary.com Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath ... - Oct 16, 2007 The Company's marketed products include Zanaflex Capsules[TM] (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Elects John P. Kelley to Board of Directors - Dec 1, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... International Business Times Acorda Therapeutics Announces $31.5 Million Financing. - Oct 4, 2006 The Company's marketed products include Zanaflex Capsules[TM] (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine... - Jun 6, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Present at the BMO Capital Markets Sixth... - Dec 1, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at the Cowen and Company 28th Annual … - Mar 10, 2008 ...including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules([R]) (tizanidine hydrochloride), the risk of unfavorable ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Conference Call and Webcast to Report … - Aug 7, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at Two Upcoming Conferences. - May 8, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics, Inc. Announces Exercise of Option by Underwriter - Aug 19, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at the Piper Jaffray Second Annual … - Jun 14, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Analyst and Investor Day - Jul 6, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Names Thomas C. Wessel, MD, Ph.D., as Chief … - Nov 12, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Reports Fourth Quarter and Full Year 2006 … - Feb 20, 2007 ...the expansion of its Zanaflex Capsules(TM) (tizanidine hydrochloride) sales force from 32 to 65 professionals and other Zanaflex Capsules operations. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Receives Additional $5 Million from Paul Capital ... - Feb 7, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Joins Russell 3000 Index - Jul 2, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at 7th Annual Fortis Biotech Conference - Apr 18, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial of... - Nov 30, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data … - Mar 19, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Announces Exercise of Option by Underwriters. - Jul 6, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Present at the Bear Stearns 20th Annual … - Sep 4, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Analyst and Investor Reception. - Apr 25, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Names Ian Smith, CFO of Vertex, to Board of … - Feb 5, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at the 25th Annual JP Morgan Healthcare... - Jan 3, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Announces Resignation of Mary Fisher - Jul 20, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics to Present at the Cowen and Company 27th Annual … - Mar 6, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics, Inc. Announces Proposed Public Offering of … - Jun 4, 2007 The Company's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics, Inc. Announces Exercise of Option by Underwriters - Feb 14, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Lifescience-online Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive … - Jun 20, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Adds Lorin J. Randall to Board of Directors. - Mar 10, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Conference Call to Report Second Quarter ... - Jul 27, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Conference Call and Webcast to Report … - Jul 31, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Present at the 2008 Deutsche Bank Biotech … - Nov 5, 2008 The Company's marketed products include Zanaflex Capsules ® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... International Business Times Acorda Therapeutics to Host Conference Call to Report First Quarter... - Apr 28, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Conference Call to Report Third Quarter … - Oct 26, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics to Host Conference Call to Report Fourth Quarter ... - Mar 24, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics Announces Directors Stepping Down. - Aug 7, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Free with registration - Business Wire - AccessMyLibrary.com Acorda Therapeutics.(Update) - Feb 1, 2007 The sales team promotes Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Free with registration - Medical Marketing & Media - AccessMyLibrary.com Acorda Therapeutics Signs GGF2 Manufacturing Agreement with CMC … - Apr 9, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most … - Aug 21, 2008 The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... RedOrbit Acorda Therapeutics to Present at the Rodman & Renshaw 8th Annual … - Oct 30, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... Genetic Engineering News - Genetic Engineering News (press release) Acorda Therapeutics Selected to be Inaugural Member of the NASDAQ … - Sep 25, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at the Lazard Capital Markets Third … - Nov 20, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics(R) Announces Completion of Enrollment in … - Mar 3, 2006 Acorda also announced that it has expanded its in-house, specialty sales force for Zanaflex Capsules(TM) (tizanidine hydrochloride) from 14 to 32. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at Two Upcoming Conferences.( … - Nov 20, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at the JPMorgan 26th Annual Healthcare... - Dec 31, 2007 ...including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules([R])(tizanidine hydrochloride), the risk of unfavorable results ... $4.95 - Business Wire - ECNext Press Release: Acorda Therapeutics Receives and Responds to Third … - Feb 26, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Pay-Per-View - M2 Presswire - HighBeam Research Acorda Therapeutics to Present at the BioCentury Newsmakers in the … - Aug 31, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Clinical Trials; Acorda Therapeutics completes enrollment in Fampridin... - Apr 4, 2006 Acorda also announced that it has expanded its in-house, specialty sales force for Zanaflex Capsules (tizanidine hydrochloride) from 14 to 32. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Ph III trial of Acorda's MS drug completes enrollment.(Acorda … - Mar 13, 2006 The New York-headquartered firm has also expanded the in-house, specialty sales force for its spasticity drug Zanaflex (tizanidine hydrochloride) from 14 to ... $4.95 - Pharma Marketletter - ECNext Acorda Therapeutics has completed the expansion of its sales force.( … - Mar 1, 2007 Acorda Therapeutics has completed the expansion of its sales force to 65 people to promote Zanaflex Capsules (tizanidine hydrochloride) for the management ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Caraco to offer OTC Versions of Zyrtec for youngsters.(OT-Cs)(Caraco ... - Feb 4, 2008 Caraco Pharmaceutical Laboratories Ltd. has received FDA approval for tizanidine hydrochloride. The product, a generic form of Elan Pharmaceutical Corp. ... Pay-Per-View - Chain Drug Review - HighBeam Research Acorda Therapeutics to Host Conference Call and Webcast to Report … - Oct 30, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics CEO Inducted into Spinal Cord Injury Hall of Fame. - Nov 9, 2007 The Company's marketed products include Zanaflex Capsules[TM] (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics Receives and Responds to Third Point Letter. - Feb 26, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - M2 Presswire - ECNext Press Release: Acorda Therapeutics Added to NASDAQ Biotechnology … - Nov 16, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Introduces Acorda Therapeutics to our Bluechips Watch ... - Jan 29, 2008 The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... Pay-Per-View - M2 Presswire - HighBeam Research Acorda Therapeutics Announces Exercise of Over-Allotment Option by … - Mar 13, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... $4.95 - Business Wire - ECNext Article: Caraco Pharmaceutical Laboratories Ltd.(In other generics... - Aug 20, 2007 Caraco Pharmaceutical Laboratories Ltd. has received FDA approval for tizanidine hydrochloride. The product, a generic form of Elan Pharmaceutical Corp. ... Pay-Per-View - Chain Drug Review - HighBeam Research Acorda Therapeutics to Host Conference Call to Report Fourth Quarter ... - Feb 13, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at the BMO Capital Markets Focus on … - Nov 27, 2007 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext Acorda Therapeutics to Present at the 18th Annual Piper Jaffray... - Nov 21, 2006 The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ... $4.95 - Business Wire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
